Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

2.8K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
2.8K
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

1.6K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.6K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

760
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
760
Insulin Secretory Vesicles01:05

Insulin Secretory Vesicles

7.2K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
7.2K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

684
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
684

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to Letter to the Editor regarding "Calcitonin gene-related peptide and headache: Comparison of two commonly used assay kits highlights the perils of measuring neuropeptides with enzyme-linked immunosorbent assays".

Headache·2026
Same author

The Concise Guide to PHARMACOLOGY 2025/26: G protein-coupled receptors.

British journal of pharmacology·2025
Same author

Calcitonin gene-related peptide and headache: Comparison of two commonly used assay kits highlights the perils of measuring neuropeptides with enzyme-linked immunosorbent assays.

Headache·2025
Same author

Decoding PACAP signaling: Splice variants, pathways and designer drugs.

Cephalalgia : an international journal of headache·2025
Same author

Development and pharmacological characterization of novel multi- calcitonin gene-related peptide and pituitary adenylate cyclase-activating peptide receptor antagonists.

Headache·2025
Same author

Pituitary adenylate cyclase-activating polypeptide signalling as a therapeutic target in migraine.

Nature reviews. Neurology·2024
Same journal

Weight loss with atogepant in the long-term treatment of migraine: An interim analysis of a safety endpoint from a phase 3, multicenter, open-label, 156-week extension study.

Headache·2026
Same journal

American Headache Society 68th Annual Scientific Meeting June 4-7, 2026, Orlando, Florida.

Headache·2026
Same journal

In Memoriam-Doctor J. Keith Campbell.

Headache·2026
Same journal

Hypothalamus as a conductor of the migraine prodrome: A narrative review.

Headache·2026
Same journal

New academic year in Headache.

Headache·2026
Same journal

Essential readings in headache medicine: Top 10 educational articles from 2025.

Headache·2026
See all related articles

Related Experiment Video

Updated: Mar 2, 2026

Author Spotlight: Investigating Islet Abnormalities and Function with a Pseudoislet Protocol
08:04

Author Spotlight: Investigating Islet Abnormalities and Function with a Pseudoislet Protocol

Published on: November 3, 2023

2.6K

Amylin.

Debbie L Hay1

  • 1School of Biological Sciences, The University of Auckland, 3A Symonds Street, Auckland 1142, New Zealand.

Headache
|May 10, 2017
PubMed
Summary
This summary is machine-generated.

Amylin, a peptide hormone, shares biological actions and a receptor with CGRP. This review explores amylin

Keywords:
CGRPamylinmigrainereceptor activity-modifying protein

More Related Videos

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.8K
An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

11.2K

Related Experiment Videos

Last Updated: Mar 2, 2026

Author Spotlight: Investigating Islet Abnormalities and Function with a Pseudoislet Protocol
08:04

Author Spotlight: Investigating Islet Abnormalities and Function with a Pseudoislet Protocol

Published on: November 3, 2023

2.6K
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.8K
An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

11.2K

Area of Science:

  • Endocrinology
  • Neuroscience
  • Pharmacology

Background:

  • Amylin is a 37 amino acid peptide hormone structurally and functionally related to calcitonin gene-related peptide (CGRP).
  • Both amylin and CGRP interact with shared receptor systems, suggesting potential overlapping biological roles.
  • CGRP is critically involved in migraine pathophysiology, driving significant therapeutic development efforts.

Purpose of the Study:

  • To review amylin biology and its therapeutic applications, particularly in diabetes.
  • To explore the potential involvement of amylin in headache disorders, drawing parallels with CGRP.
  • To highlight the AMY1 receptor as a dual target for both amylin and CGRP.

Main Methods:

  • Literature review of amylin and CGRP biology.
  • Analysis of shared receptor mechanisms.
  • Discussion of potential therapeutic implications in headache disorders.

Main Results:

  • Amylin analogs are established treatments for diabetes.
  • Amylin and CGRP share receptor components, including the AMY1 receptor.
  • The AMY1 receptor mediates bioactivity for both amylin and CGRP.

Conclusions:

  • The overlap between amylin and CGRP systems warrants investigation for potential roles in headache disorders.
  • The AMY1 receptor represents a key molecular link between amylin and CGRP signaling.
  • Understanding this dual receptor system may offer novel therapeutic strategies for migraine and related conditions.